한국어
English
日本語
中文(简体)
Lafinna Capsule 50 mg (Dabrafenib Mesilate)
59.25mg
Soft capsule · Prescription medication
Novartis Korea Co., Ltd.
Dabrafenib mesilate is an anti-cancer drug ingredient that targets BRAF mutated cancer cells.
MFDS ingredient code M260368
Dabrafenib mesilate is an anti-cancer agent that selectively inhibits the mutant form of the BRAF protein. It is primarily used for the treatment of malignant tumors that are positive for BRAF V600 mutations. This ingredient blocks the signaling pathways for cancer cell growth, thereby inhibiting tumor growth.
Dabrafenib mesilate binds to the mutated part of the BRAF protein within cancer cells and inhibits its activity. As a result, the signaling pathways that promote cancer cell proliferation are blocked, which slows the growth of tumors. Its selective action results in relatively less impact on normal cells.
Approved uses differ by product. Check each product's information for its actual use.
Dabrafenib mesilate is a targeted therapy specifically for BRAF mutation-positive cancers, which targets only specific BRAF mutations unlike other similar targeted inhibitors. This results in a differentiated side effect profile and therapeutic effectiveness. It is also formulated in a micronized form to enhance its bioavailability.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.
